ReviewDrug design, development and therapy2026
Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam is an ultra-short-acting benzodiazepine that is hydrolyzed by carboxylesterase 1 (CES1) to the inactive metabolite CNS 7054. Since regulatory approval in 2020 it has been adopted globally for procedural sedation and general anesthesia, supported by an expanding evidence base of randomized trials, population pharmacokinetic/pharmacodynamic (PK/PD) modeling studies, dose-finding sequential-allocation analyses, and meta-analyses. Synthesizing 92 studies published between January 2020 and April 2026, this narrative review defines dose optimization across diverse populations. For adult procedural sedation, a fixed 5 mg initial bolus followed by 2.5 mg maintenance titrations achieves moderate sedation with a hemodynamic and respiratory profile that compares favorably with propofol, whereas general anesthesia requires an induction rate of 6 to 12 mg kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.